Prime Medicine Inc

NASDAQ:PRMEUnited States

Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering the gene editing therapies to patients. It deploys its Prime Editing platform, a gene editing technology, to develop a new class of differentiated, one-time genetic therapies. It is engaged in developing Prime Editors as a new class of therapeutics with transformative potential to expand the application of curative precision genetic medicines. It has built a diversified portfolio of investigational therapeutic programs organized around core areas of focus, namely hematology and immunology, liver, lung, ocular and neuromuscular. The programs within its other areas of focus are on earlier stages of preclinical development and include Liver programs, such as Wilson's disease and glycogen storage disease 1b; Lung program, such as Cystic fibrosis; Ocular program, such as Retinitis pigmentosa caused by Rhodopsin mutations, and Neuromuscular programs, including Friedreich's ataxia and myotonic dystrophy type 1.

Contact Information

Headquarters

21 Erie StreetCAMBRIDGE, MA, United States 02139

Phone

617-465-0013

Fax

302-655-5049

Executives

President, Chief Executive Officer, Director

Keith Gottesdiener

Co-Founder, Head of Prime Editing Platform

Andrew Anzalone

Co-Founder

David Liu

Chief Financial Officer

Allan Reine

Senior Vice President - Strategy and Corporate Operations

Meredith Goldwasser